Special Drug Use-results Survey for Lon… | Clinical Trial

Key information

Conditions

Chronic Idiopathic Thrombocytopenic Purpura

Sex eligibility

All sexes

Study type

Observational

Primary location

Research site

Tokyo and Japanese Other Cities, Japan

Location status: Recruiting

Location contact

Kazunori Abe, director

CONTACT

[email protected]

0356843575

About this study

The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.

Treatment and study plan

Fostamatinib

Drug

oral administration

Primary outcomes

Adverse events

Time frame: 18 months

Study contacts

Contact information is provided by the study sponsor or research team.

Kazunori Abe, director

CONTACT

[email protected]

0356843575

Sponsors and collaborators

Lead sponsor

Kissei Pharmaceutical Co., Ltd.

Industry

Registry information

Important dates

Study start: 2023
Primary completion: 2028
Study completion: 2028
First posted: Jan 3, 2025
Registry last updated: Jan 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed